New drug aims to tame overactive thyroid in Graves' disease
NCT ID NCT07661056
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This study tests whether BHV-1300 can help adults with Graves' disease achieve normal thyroid function without antithyroid drugs. Participants receive either BHV-1300 or a placebo via injection. The main goal is to see if more people on BHV-1300 have normal thyroid hormone levels at 26 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BHV-1300
What this could lead to
If successful, BHV-1300 could offer a new treatment option for Graves' disease that helps patients achieve normal thyroid function without needing antithyroid drugs.
What could go wrong
This is an early phase 3 trial, so results may not confirm benefit. The drug may cause side effects or fail to outperform placebo. Long-term safety and efficacy are not yet established.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAVES DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site-008
RECRUITINGCanton, Ohio, 44718, United States
-
Site-025
RECRUITINGLenexa, Kansas, 66234, United States
-
Site-032
RECRUITINGBurbank, California, 91501, United States
-
Site-054
RECRUITINGMcKinney, Texas, 75069, United States
-
Site-067
RECRUITINGWalnut Creek, California, 94598, United States